Alert

Recommended Alerts

Sign Up For Alerts

Medicare Expands Coverage of “Breakthrough” Medical Devices and Codifies “Reasonable and Necessary” Standard

On January 14, 2021, the Centers for Medicare and Medicaid Services (“CMS”) published a final rule that significantly alters the Medicare reimbursement landscape for medical devices approved under the Food and Drug Administration’s (“FDA”) “Breakthrough Devices Program.” The rule, which represents the culmination of years of advocacy by the medical device industry and patient and provider interest groups, finalizes a September 1, 2020 proposed rule that aimed to address the substantial time lag between FDA authorization of medical devices and Medicare coverage of the same. Specifically, the rule establishes a Medicare Coverage of Innovative Technology (“MCIT”) pathway for Medicare coverage of Breakthrough Devices and related medical procedures during a four-year period that begins immediately upon FDA marketing authorization. The final rule also codifies the definition of the “reasonable and necessary” standard that is used to determine when other items and services (and MCIT devices after the four-year period) may be covered by the Medicare program. The new rule becomes effective March 15, 2021.

Read More

India Finalizes Rules Regarding Compensation for Subjects Injured in Clinical Trials and Post-Trial Access to Study Drugs


Time to Read: 3 minutes Practices: Health Care

Printer-Friendly Version

I. Background

Since 2013, India’s clinical trials regulatory framework has undergone continuous, significant changes to bolster protections for clinical trial participants. In an effort to clarify these evolving requirements relating to clinical trials, on February 1, 2018, India’s Ministry of Health and Family Welfare (the “MoHFW”), in supersession of India’s Drugs and Cosmetics Rules, 1945, issued new draft rules pertaining to clinical trials (the “2018 Draft Rules”). The MoHFW has now released finalized rules via notification dated March 19, 2019, entitled the “New Drugs and Clinical Trials Rules, 2019” (“2019 Rules”).1 As with the 2018 Draft Rules, these finalized rules consolidate and clarify the myriad notices, orders, and other regulatory notifications issued by the Indian government over the past few years, and reflect ongoing efforts to improving India’s clinical trial regulatory framework.

The 2019 Rules, among other changes, provide clarity through new definitions, add additional provisions regarding research ethics committees, and expedite the application process for new clinical trials, including by limiting the processing time to 30 days for an application to conduct a clinical trial of a new drug that was either discovered in India or will be manufactured and marketed in India.2 This Alert provides a high-level description of other key provisions of the 2019 Rules.

II. Compensation for Subjects Injured in the Course of Clinical Trials

For several years, India has imposed stringent obligations on the part of the sponsor to provide compensation to clinical trial participants for injuries suffered that are deemed related to the trial. The 2019 Rules preserve these fairly controversial and broad compensation-related requirements, though – in an improvement over past rules – any such compensation for injury will now ultimately be determined by the Drug Controller General of India based on recommendations from an expert committee, instead of based on the decision of an ethics committee, which generally are ill-equipped to make such an assessment. The 2019 Rules also retain the requirement that sponsors provide free medical management to study participants that have experienced an injury per the investigator’s opinion or until it is established that the injury is unrelated to the study.

In addition, the 2019 Rules have finalized the inclusion of the helpful compensation formulae that had been developed by the MoHFW (based on certain factors, such as age of the subject), which introduces clarity and defines the limit of financial liability on the part of the sponsor for certain injuries.3

III. Recording of Informed Consent Process and Post-Trial Study Drug Access

These finalized rules also preserve another controversial requirement that has been in place for several years, specifically, that investigators maintain an audio-video recording of the informed consent process for vulnerable subjects in clinical trials of new chemical or molecular entities (but requiring audio recording only for cases “of clinical trial of anti-HIV and anti-leprosy drugs”).4

India also has viewed favorably participant post-trial access to a study drug, with the 2019 Rules finalizing post-access requirements, requiring sponsors to provide post-trial access to a drug at no cost to the trial participant if (1) the investigator has recommended such post-trial access for an individual after completion of a trial, (2) the trial relates to an indication for which no alternative therapy is available and the drug has been found beneficial to the subject by the investigator, (3) the ethics committee has approved the continued access, (4) the subject consents to post-trial use of the investigational drug, and (5) the investigator has certified and the trial subject declares in writing that for such post-trial use the “sponsor shall have no liability for post-trial use of investigational new drug or new drug.”5

The 2019 Rules also provide a term for orphan drugs, now defined as drugs intended to treat conditions that affect not more than 500,000 persons in India, and contemplate fee waivers for applications to conduct clinical trials for such drugs in India.6

* * *

While certain requirements under India’s clinical trials regulatory framework might still be in need of further clarification, these changes – and other significant developments set forth in the 2019 Rules – represent an incrementally favorable development in India’s clinical trials regulations.

  1. New Drugs and Clinical Trials Rules, 2019, Ministry of Health & Fam. Welfare, Notification, G.S.R. 227(E), (March 19, 2019), [hereinafter, the “2019 Rules”].
  2. Id. at Ch. V, Section 23.
  3. Id. at Seventh Schedule.
  4. Id. at Third Schedule, Section 2(g).
  5. Id. at Ch. V, Section 27.
  6. Id. at Ch. 1, Section 2(x); Sixth Schedule.
  7. back to top

Printer-Friendly Version

Cookie Settings